This Article Figures Only Full Text Full Text (PDF) Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garg, S. Articles by Serruys, P. W. Search for Related Content PubMed PubMed Citation Articles by Garg, S. Articles by Serruys, P. W.

STATE-OF-THE-ART PAPER

Coronary Stents

Looking Forward

Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands

Manuscript received December 9, 2009; revised manuscript received June 1, 2010, accepted June 15, 2010.

^_* Reprint requests and correspondence: Prof. Patrick W. Serruys, Ba583a, Thoraxcenter, Erasmus Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands (Email: p.w.j.c.serruys{at}erasmusmc.nl).

Despite all the benefits of drug-eluting stents (DES), concerns have been raised over their long-term safety, with particular reference to stent thrombosis. In an effort to address these concerns, newer stents have been developed that include: DES with biodegradable polymers, DES that are polymer free, stents with novel coatings, and completely biodegradable stents. Many of these stents are currently undergoing pre-clinical and clinical trials; however, early results seem promising. This paper reviews the current status of this new technology, together with other new coronary devices such as bifurcation stents and drug-eluting balloons, as efforts continue to design the ideal coronary stent.

Key Words: drug-eluting stents • biodegradable stents • biodegradable polymer stents • polymer-free drug-eluting stents • coronary stents

Abbreviations and Acronyms   BDS = biodegradable stent   BE = balloon-expandable   BMS = bare-metal stent(s)   BVS = bioresorbable vascular scaffold   C.E. = Conformité Européene   DAPT = dual antiplatelet therapy   DEB = drug-eluting balloon   DES = drug-eluting stent(s)   EES = everolimus-eluting stent(s)   EPC = endothelial progenitor cell   FDA = Food and Drug Administration   FIM = first in man   ISR = in-stent restenosis   IVUS = intravascular ultrasound   IVUS-VH = intravascular ultrasound-virtual histology   MACE = major adverse cardiovascular events   MI = myocardial infarction   NES = novolimus-eluting stent(s)   OCT = optical coherence tomography   PCI = percutaneous coronary intervention   PES = paclitaxel-eluting stent(s)   PF = polymer-free   PLA = poly-L-lactide   PLGA = 50:50 poly DL-lactide-co-glycolide   PLLA = poly-L-lactic acid   SES = sirolimus-eluting stent(s)   SE = self-expanding   ST = stent thrombosis   TLR = target lesion revascularization   TVR = target vessel revascularization   ZES = zotarolimus-eluting stent(s)

This article has been cited by other articles:

				P. W. Serruys, Y. Onuma, D. Dudek, P. C. Smits, J. Koolen, B. Chevalier, B. de Bruyne, L. Thuesen, D. McClean, R.-J. van Geuns, et al. Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes J. Am. Coll. Cardiol., October 4, 2011; 58(15): 1578 - 1588. [Abstract] [Full Text] [PDF]

				E. R. Bates and D. S. Menees My Stent Is Better Than Your Stent...Or Is It? J. Am. Coll. Cardiol. Intv., May 1, 2011; 4(5): 551 - 553. [Full Text] [PDF]

				J. A. Bittl Bioresorbable Stents: The Next Revolution Circulation, November 30, 2010; 122(22): 2236 - 2238. [Full Text] [PDF]